The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have discovered isoindolinone aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatement of cancer and fibrosis.

Cambridge Enterprise and European Molecular Biology Laboratory have presented new peptides derived from full-length factor V (FV) protein acting as T-cell activation inhibitors reported to be useful for the treatment of inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, psoriasis, vasculitis, idiopathic pulmonary fibrosis, vitiligo and lupus nephritis, among other disorders.

3B Pharmaceuticals has divulged conjugates comprising fibroblast activation protein alpha (FAPalpha) inhibitors covalently linked to radiolabeled chelating agents through a linker acting as single-photon emission computed tomography (SPECT)/CT imaging agents reported to be useful for the diagnosis and treatment of cancer.

Oncobix has discovered Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of multiple sclerosis, inflammation, urticaria, systemic lupus erythematosus, allergy, rheumatoid arthritis, asthma and leukemia.

Jing Medicine Technology has described new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a mothers against decapentaplegic homolog 3 (SMAD3)-targeting moiety through a linker reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and autoimmune disease.